News provider CB Insights said, apart from Kaiser Permanente Ventures, the other investors in the round were venture capital firms
CytoPherx, a US-based medical device maker for inflammation-based diseases, has raised $34m in its series C round from a consortium including healthcare provider Kaiser Permanente’s corporate venturing unit.
News provider CB Insights said, apart from Kaiser Permanente Ventures, the other investors in the round were venture capital firms Early Stage Partners, Onset Ventures, Capital Midwest Fund, Emergent Medical Partners, Charter Oak Private Equity, Aphelion Capital, Lurie Investment Fund, Apjohn Ventures and North Coast Technology Investors as well as the…
